Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Angiopoietin-1 (Ang1) activation of Tie2 receptors on endothelial cells (ECs) reduces adhesion by tumor cells (TCs) and limits junctional permeability to TC diapedesis. We hypothesized that systemic therapy with Vasculotide (VT)-a purported Ang1 mimetic, Tie2 agonist-can reduce the extravasation of potentially metastatic circulating TCs by similarly stabilizing the host vasculature. In vitro, VT and Ang1 treatments impeded endothelial hypermeability and the transendothelial migration of MDA-MB-231∙LM2-4 (breast), HT29 (colon), or SN12 (renal) cancer cells to varying degrees. In mice, VT treatment inhibited the transit of TCs through the pulmonary endothelium, but not the hepatic or lymphatic endothelium. In the in vivo LM2-4 model, VT monotherapy had no effect on primary tumors, but significantly delayed distant metastatic dissemination to the lungs. In the post-surgical adjuvant treatment setting, VT therapeutically complemented sunitinib therapy, an anti-angiogenic tyrosine kinase inhibitor which limited the local growth of residual disease. Unexpectedly, detailed investigations into the putative mechanism of action of VT revealed no evidence of Tie2 agonism or Tie2 binding; alternative mechanisms have yet to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fiedler, U., Reiss, Y., Scharpfenecker, M., Grunow, V., Koidl, S., Thurston, G., Gale, N. W., Witzenrath, M., Rosseau, S., Suttorp, N., et al. (2006) · Nature Medicine · doi:10.1038/nm1351 · Cited by 933 · cited 2×
“Most cancer drugs are selected from preclinical studies based on their potency at inhibiting primary tumor growth, and brought into clinical trials with the rationale that they will similarly inhibit the growth of metastases (Francia et al , 2011; Guerin et al , 2013).”
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685 · cited 1×
“…clinically for patients with advanced metastatic breast cancer (MBC) — especially with sunitinib (SU) treatment, which when given as a monotherapy or combined with conventional chemotherapies has repeatedly failed in multiple phase III clinical trials (Ebos & Kerbel, 2011; Mackey et al , 2012).”
Self-citationMazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.005 · Cited by 639
Cooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.024 · Cited by 530
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling
Felcht, M., Luck, R., Schering, A., Seidel, P., Srivastava, K., Hu, J., Bartol, A., Kienast, Y., Vettel, C., Loos, E. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58832 · Cited by 479 · cited 1×
“…many cytokines, including angiopoietin-1 (Ang1), a guardian of EC quiescence (Augustin et al , 2009; Huang et al , 2010), as well as angiopoietin-2 (Ang2) and vascular endothelial growth factor (VEGF), the cooperative initiator and driver of angiogenesis (Huang et al , 2010; Felcht et al , 2012).”
Davis, S., Papadopoulos, N., Aldrich, T. H., Maisonpierre, P. C., Huang, T., Kovac, L., Xu, A., Leidich, R., Radziejewska, E., Rafique, A., et al. (2003) · Nature Structural Biology · doi:10.1038/nsb880 · Cited by 234
Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis
Holopainen, T., Saharinen, P., D’Amico, G., Lampinen, A., Eklund, L., Sormunen, R., Anisimov, A., Zarkada, G., Lohela, M., Heloterä, H., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs009 · Cited by 216
Oligomerization and Multimerization Are Critical for Angiopoietin-1 to Bind and Phosphorylate Tie2
Kim, K.-T., Choi, H.-H., Steinmetz, M. O., Maco, B., Kammerer, R. A., Ahn, S. Y., Kim, H.-Z., Lee, G. M., & Koh, G. Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500292200 · Cited by 170 · cited 1×
“Their monomeric structures are highly similar, but Ang1 predominantly exists in higher-order multimeric forms, while Ang2 mainly exists in dimeric form (Davis et al , 2003; Cho et al , 2004; Kim et al , 2005).”
Rini, B., Szczylik, C., Tannir, N. M., Koralewski, P., Tomczak, P., Deptala, A., Dirix, L. Y., Fishman, M., Ramlau, R., Ravaud, A., et al. (2012) · Cancer · doi:10.1002/cncr.27632 · Cited by 110 · cited 1×
“Trebananib had also failed in phase II trials involving metastatic gastro-esophageal (Eatock et al , 2013), colorectal (Peeters et al , 2013), and clear-cell renal (Rini et al , 2012) carcinomas.”
Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality
David, S., Ghosh, C. C., Kümpers, P., Shushakova, N., Van Slyke, P., Khankin, E. V., Karumanchi, S. A., Dumont, D., & Parikh, S. M. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00459.2010 · Cited by 96 · cited 5×
“For instance, in endotoxemic mice, VT prevented inflammatory induction of lung vascular hyperpermeability by preserving VE-cadherin-mediated EC junctions (David et al , 2011).”
InfluentialJumping the barrier: VE‐cadherin, VEGF and other angiogenic modifiers in cancer
Le Guelte, A., Dwyer, J., & Gavard, J. (2011) · Biology of the Cell · doi:10.1042/bc20110069 · Cited by 91 · cited 3×
“…counteracts Src-mediated destabilization of paracellular VE-cadherin junctions and IP 3 /eNOS-mediated calcium influxes in ECs — which together cause vascular hyperpermeability and lowered resistance to TC diapedesis (Gamble et al , 2000; Gavard et al , 2008; Le Guelte et al , 2011; Koh, 2013).”
Peeters, M., Strickland, A. H., Lichinitser, M., Suresh, A. V. S., Manikhas, G., Shapiro, J., Rogowski, W., Huang, X., Wu, B., Warner, D., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.594 · Cited by 79 · cited 1×
“Trebananib had also failed in phase II trials involving metastatic gastro-esophageal (Eatock et al , 2013), colorectal (Peeters et al , 2013), and clear-cell renal (Rini et al , 2012) carcinomas.”
Eatock, M. M., Tebbutt, N. C., Bampton, C. L., Strickland, A. H., Valladares-Ayerbes, M., Swieboda-Sadlej, A., Van Cutsem, E., Nanayakkara, N., Sun, Y.-N., Zhong, Z. D., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds502 · Cited by 64 · cited 1×
“Trebananib had also failed in phase II trials involving metastatic gastro-esophageal (Eatock et al , 2013), colorectal (Peeters et al , 2013), and clear-cell renal (Rini et al , 2012) carcinomas.”
Cited by
Regula, J. T., Lundh von Leithner, P., Foxton, R., Barathi, V. A., Cheung, C. M. G., Bo Tun, S. B., Wey, Y. S., Iwata, D., Dostalek, M., Moelleken, J., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505889 · Cited by 376
Passing the Vascular Barrier: Endothelial Signaling Processes Controlling Extravasation
Wettschureck, N., Strilic, B., & Offermanns, S. (2019) · Physiological Reviews · doi:10.1152/physrev.00037.2018 · Cited by 286
Amelioration of sepsis by TIE2 activation–induced vascular protection
Han, S., Lee, S.-J., Kim, K. E., Lee, H. S., Oh, N., Park, I., Ko, E., Oh, S. J., Lee, Y.-S., Kim, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9260 · Cited by 203
Wu, F. T. H., Man, S., Xu, P., Chow, A., Paez-Ribes, M., Lee, C. R., Pirie-Shepherd, S. R., Emmenegger, U., & Kerbel, R. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0888 · Cited by 58
“ELISA measurement of angiogenic factors Harvested lung and kidney tissues were snap-frozen in liquid nitrogen and homogenized in RIPA lysis buffer (27).”
MethodSelf-citationWu, F. T. H., Xu, P., Chow, A., Man, S., Krüger, J., Khan, K. A., Paez-Ribes, M., Pham, E., & Kerbel, R. S. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0297-1 · Cited by 47
Self-citation
Metadata
- Authors
- Wu, F. T., Lee, C. R., Bogdanovic, E., Prodeus, A., Gariépy, J., & Kerbel, R. S.
- Venue
- EMBO Molecular Medicine
- Published
- 2015-04-07
- Volume
- 7
- Issue
- 6
- Pages
- 770-787
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2135398396
- Cited by
- 38
- References
- 13
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.